• Conditions and diseases

  • Blood and immune system •
  • Cancer •
  • Cardiovascular •
  • Central nervous system •
  • Digestive system •
  • Ear and nose •
  • Endocrine, nutritional and metabolic •
  • Eye •
  • Gynaecology, pregnancy and birth •
  • Infectious diseases •
  • Injuries, accidents and wounds •
  • Mental health and behavioural conditions •
  • Mouth and dental •
  • Musculoskeletal •
  • Respiratory •
  • Skin •
  • Urogenital

• Public health

  • Accidents and injuries •
  • Alcohol •
  • Behaviour change •
  • Cancer •
  • Cardiovascular disease •
  • Child health •
  • Child social care •
  • Chronic illness •
  • Diabetes •
  • Drugs •
  • Environmental health •
  • Infectious diseases •
  • Maternal health •
  • Mental health •
  • Non-communicable diseases •
  • Obesity and diet •
  • Occupational health •
  • Older people •
  • Physical activity •
  • Sexual health •
  • Smoking and tobacco •
  • Transport •
  • Vaccine preventable diseases •
  • Working with and involving communities

• Treatments, Procedures and Devices

  • Bones and joint surgery •
  • Cardiovascular surgery •
  • Cardiovascular system drug treatments •
  • Clinical devices •
  • Diagnostic imaging •
  • Diagnostic procedures •
  • Digestive tract and other abdominal organs surgery •
  • Drug treatments •
  • Endocrine system and breast surgery •
  • Eye surgery •
  • Nervous system surgery •
  • Radiotherapy •
  • Screening •
  • Surgical procedures •
  • Therapeutic procedures •
  • Tissue and organ donation •
  • Urogenital surgery

• Guidance by type

  • Clinical Guidelines •
  • Technology appraisals •
  • Public health guidance •
  • Diagnostics guidance •
  • Interventional procedures guidance •
  • Medical technologies guidance •
  • Cancer service guidance •
  • Quality standards

• Guidance by date

  • View the guidance by date published

About NICE guidance Close

Navigation

• NICE guidance

• Find guidance
• NICE Pathways
• Latest guidance
• Guidance by type
• Guidance in development
• How guidance is produced
• NICE guidance research recommendations
• Guidance for patients and public
• Other publications
• Patient safety solutions pilot
• Quality standards

Growth failure (in children) - human growth hormone (HGH) (review)

Human growth hormone for the treatment growth failure in children (review)

Status:	History
Expected date of issue:	TBC
Wave:	R
Process:	MTA
Topic area: Endocrine, nutritional and metabolic Therapeutic procedures

Project team | Schedule | Stakeholders | Project history | Key documents

 

NICE project team

Executive Lead:	Andrew Dillon
Technical Lead:	Fay McCracken
Communications manager:	Philip Ranson
Project manager:	Jeremy Powell
Assessment group:	Southampton Health Technology Assessment Centre (SHTAC), University of Southampton

Top

 

Provisional schedule

Consultation on draft scope by stakeholders:	4 April 2008
Information meeting with consultees:	13 June 2008
Closing date for invited submissions / evidence submission:	27 February 2009
Final scope published:	August 2008
1st appraisal committee meeting:	03 November 2009
2nd appraisal committee meeting:	04 February 2010

Top

 

Consultees and commentators

Consultees Commentators (no right to submit or appeal) Manufacturers/sponsors Eli Lilly & Co Ltd (somatropin) Ferring Pharmaceuticals (UK) (somatropin) Ipsen Ltd (somatropin) MerckSerono (somatropin) Novo Nordisk Ltd (somatropin) Pfizer Ltd (somatropin) Sandoz Limited (somatropin) Patient/carer groups Child Growth Foundation Pituitary Foundation Turner Syndrome Support Society Professional groups British Society For Paediatric Endocrinology and Diabetes Royal College of Nursing Royal College of Paediatrics & Child Health Royal College of Pathologists Royal College of Physicians Society for Endocrinology Others Department of Health Welsh Assembly Government General British National Formulary Department of Health, Social Services and Public Safety for Northern Ireland Medicines and Healthcare products Regulatory Agency (MHRA) NHS Quality Improvement Scotland Comparator manufacturers None Relevant research groups None Assessment team Southampton Health Technology Assessment Centre (SHTAC), University of Southampton National Coordinating Centre for Health Technology Assessment Associated Guideline Groups None Associated Public Health Groups None

Top

 

Project history

Date Update 9 June 2005 Topic created. 8 November 2006 On reviewing the consultation responses, in particular information from the manufacturers of the technologies for this appraisal, NICE has decided to postpone initiating the appraisal to update the existing guidance, to allow for pending new indications to receive regulatory approval.  We intend to set the timelines of the appraisal to coincide with the licensing process for these indications and will provide detailed appraisal timelines when we have more precise information. 30 November 2007 On reviewing responses in regards to the scope the Institute is currently liaising with the Department of Health on the possibility of splitting the scope in two. 11 March 2008 Confirmation regarding a split in the scope and the technology appraisal to resume. This technology appraisal to consult in draft scope and provide a post referral scoping workshop for consultees in June 2008.

Top

 

Key documents

Growth failure (in children) - human growth hormone (HGH) (review): final appraisal determination 18 March 2010 Growth failure (in children) - human growth hormone (HGH) (review): appraisal consultation 02 December 2009 Growth failure (in children) - human growth hormone (HGH) (review): final protocol 25 September 2008 Growth failure in (children) - human growth hormone (HGH) (review): final scope 12 September 2008 Growth failure in (children) - human growth hormone (HGH) (review): comments on the draft scope 12 September 2008 Growth failure in (children) - human growth hormone (HGH) (review): comments on the provisional matrix 12 September 2008 Growth failure (in children) - human growth hormone (HGH) (review): letter to stakeholders regarding the decision to split the scope 14 April 2008 Growth failure (in children) - human growth hormone (HGH) (review): draft scope (re-issued April 2008) 14 April 2008 Growth failure (in children) - human growth hormone (HGH): provisional matrix of consultees 14 April 2008 Growth failure (in children) - human growth hormone (HGH): original draft scope 30 November 2007 Growth failure (in children) - human growth hormone (HGH): email letter to consultees and commentators 23 November 2007

This page was last updated: 27 May 2010